4xdk
From Proteopedia
(Difference between revisions)
m (Protected "4xdk" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | ''' | + | ==Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1) in complex with norfluoxetine== |
| - | + | <StructureSection load='4xdk' size='340' side='right' caption='[[4xdk]], [[Resolution|resolution]] 3.60Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[4xdk]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XDK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4XDK FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=405:(3S)-3-PHENYL-3-[4-(TRIFLUOROMETHYL)PHENOXY]PROPAN-1-AMINE'>405</scene>, <scene name='pdbligand=408:(3R)-3-PHENYL-3-[4-(TRIFLUOROMETHYL)PHENOXY]PROPAN-1-AMINE'>408</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PC1:1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE'>PC1</scene></td></tr> | |
| - | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4bw5|4bw5]]</td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4xdk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xdk OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4xdk RCSB], [http://www.ebi.ac.uk/pdbsum/4xdk PDBsum]</span></td></tr> | |
| - | [[Category: | + | </table> |
| - | [[Category: | + | == Function == |
| - | [[Category: | + | [[http://www.uniprot.org/uniprot/KCNKA_HUMAN KCNKA_HUMAN]] Outward rectifying potassium channel. Produces rapidly activating and non-inactivating outward rectifier K(+) currents. Activated by arachidonic acid and other naturally occurring unsaturated free fatty acids. |
| - | [[Category: | + | __TOC__ |
| - | [[Category: | + | </StructureSection> |
| - | [[Category: | + | [[Category: ARROWSMITH, C H]] |
| - | [[Category: | + | [[Category: BOUNTRA, C]] |
| - | [[Category: | + | [[Category: BURGESS-BROWN, N A]] |
| - | [[Category: | + | [[Category: CARPENTER, E P]] |
| - | [[Category: | + | [[Category: DONG, Y Y]] |
| - | [[Category: | + | [[Category: EDWARDS, A M]] |
| + | [[Category: MACKENZIE, A]] | ||
| + | [[Category: MUKHOPADHYAY, S]] | ||
| + | [[Category: PIKE, A C.W]] | ||
| + | [[Category: Structural genomic]] | ||
| + | [[Category: K2p]] | ||
| + | [[Category: Membrane protein]] | ||
| + | [[Category: Outward rectification]] | ||
| + | [[Category: Sgc]] | ||
| + | [[Category: Transport protein]] | ||
Revision as of 12:17, 18 March 2015
Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1) in complex with norfluoxetine
| |||||||||||
